Acrodermatitis chronica atrophicans: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(32 intermediate revisions by 8 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Infobox_Disease
'''For patient information, click [[Acrodermatitis chronica atrophicans (patient information)|here]]'''
| Name          = {{PAGENAME}}
{{ACA}}
| Image          =
{{CMG}}; {{AE}} {{Anahita}} {{RT}}
| Caption        =
| DiseasesDB    = 32940
| ICD10          = {{ICD10|L|90|4|l|80}}
| ICD9          = {{ICD9|701.8}}
| ICDO          =
| OMIM          =
| MedlinePlus    =
| eMedicineSubj  =
| eMedicineTopic =
| MeshID        =
}}
{{SI}}
{{CMG}}; {{AE}} {{RT}}


{{SK}}  Pick-Herxheimer disease  
{{SK}}  Pick-Herxheimer disease; Herxheimer disease; primary diffuse atrophy; ACA


==Overview==
==[[Acrodermatitis chronica atrophicans overview|Overview]]==
'''Acrodermatitis chronica atrophicans''' (ACA) is a [[skin rash]] indicative of the third or late stage of European [[Lyme Disease|Lyme borreliosis]].
==[[Acrodermatitis chronica atrophicans historical perspective|Historical Perspective]]==
 
==[[Acrodermatitis chronica atrophicans pathophysiology|Pathophysiology]]==
ACA is a [[dermatology|dermatological]] condition that takes a chronically progressive course and finally leads to a widespread [[atrophy]] of the [[skin]].  Involvement of the [[peripheral nervous system]] is often observed, specifically [[polyneuropathy]].
==[[Acrodermatitis chronica atrophicans causes|Causes]]==
 
==[[Acrodermatitis chronica atrophicans differential diagnosis|Differentiating Acrodermatitis chronica atrophicans from other Diseases]]==
==Historical Perspective==
==[[Acrodermatitis chronica atrophicans epidemiology and demographics|Epidemiology and Demographics]]==
The first record of ACA was made in 1883 in Breslau, Germany, where a physician named Alfred Buchwald first delineated it.
==[[Acrodermatitis chronica atrophicans risk factors|Risk Factors]]==
 
==[[Acrodermatitis_chronica_atrophicans_natural_history,_complications_and_prognosis|Natural History, Complications and Prognosis]]==
[[Herxheimer reaction|Herxheimer]] and Hartmann described it in 1902 as a "tissue paper" like [[cutaneous]] atrophy.
 
==Pathophysiology==
This progressive skin process is due to the effect of continuing active infection with the [[spirochete]] [[Lyme disease microbiology|Borrelia afzelii]]. B afzelii is the predominant pathophysiology, but may not be the exclusive, [[etiology|etiologic]] agent of ACA. Borrelia garinii, has also been detected.
 
==Natural History, Complications and Prognosis==
The course of ACA is long-standing, from a few to several years, and it leads to extensive atrophy of the skin and, in some patients, to the limitation of upper and lower limb [[joint]] mobility.     
 
The outlook is good if the acute inflammatory stage of ACA is treated adequately. The therapeutic outcome is difficult to assess in patients with the chronic atrophic phase, in which many changes are only partially reversible.


==Diagnosis==
==Diagnosis==
===Symptoms===
[[Acrodermatitis chronica atrophicans history and symptoms|History and Symptoms]] | [[Acrodermatitis chronica atrophicans physical examination|Physical Examination]] | [[Acrodermatitis chronica atrophicans laboratory findings|Laboratory Findings]] | [[Acrodermatitis chronica atrophicans other diagnostic studies|Other Diagnostic Studies]]
The rash caused by ACA is most evident on the extremities or limbs beginning with an [[inflammatory]] stage with bluish red discoloration and cutaneous [[swelling]] and concluding several months or years later with an atrophic phase. [[Sclerosis|Sclerotic]] skin plaques may also develop.
==Treatment==
 
[[Acrodermatitis chronica atrophicans medical therapy|Medical Therapy]] | [[Acrodermatitis chronica atrophicans primary prevention|Primary Prevention]] | [[Acrodermatitis chronica atrophicans secondary prevention|Secondary Prevention]] | [[Acrodermatitis chronica atrophicans cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Acrodermatitis chronica atrophicans future or investigational therapies|Future or Investigational Therapies]]
As ACA progresses the skin begins to [[wrinkle]].
 
 
===Laboratory Findings===
Physicians should use [[serology|serologic]] and [[histology|histologic]] examination to confirm the diagnosis of ACA. 


==Treatment==
==Case Studies==
Treatment consists of antibiotics including [[doxycycline]] and [[penicillin]] for up to four weeks in the acute case.
[[Acrodermatitis chronica atrophicans case study one|Case #1]]


==See also==
==Related Chapters==
*[[Lyme Disease]]
*[[Lyme Disease]]
*[[erythema migrans|Erythema Migrans]]
*[[erythema migrans|Erythema Migrans]]


==External links==
==References==
*[http://www.dermis.net/dermisroot/en/35111/diagnose.htm DermIs.net Picture of Acrodermatitis chronica atrophicans rashes]
{{reflist|2}}


{{Diseases of the skin and subcutaneous tissue}}
{{Diseases of the skin and subcutaneous tissue}}
Line 61: Line 34:
[[Category:Disease]]
[[Category:Disease]]
[[Category:Dermatology]]
[[Category:Dermatology]]
[[Category:Symptoms]]
[[Category:Insect-borne diseases]]
[[Category:Insect-borne diseases]]
[[Category:Lyme disease]]
[[Category:Lyme disease]]
[[Category:Zoonoses]]
[[Category:Zoonoses]]
[[Category:Spirochaetes]]
[[Category:Spirochaetes]]
[[Category:Infectious disease|*]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Latest revision as of 07:54, 4 August 2022

For patient information, click here

Acrodermatitis chronica atrophicans Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Acrodermatitis chronica atrophicans from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acrodermatitis chronica atrophicans On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acrodermatitis chronica atrophicans

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acrodermatitis chronica atrophicans

CDC on Acrodermatitis chronica atrophicans

Acrodermatitis chronica atrophicans in the news

Blogs on Acrodermatitis chronica atrophicans

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Acrodermatitis chronica atrophicans

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2] Raviteja Guddeti, M.B.B.S. [3]

Synonyms and keywords: Pick-Herxheimer disease; Herxheimer disease; primary diffuse atrophy; ACA

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Acrodermatitis chronica atrophicans from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1

Related Chapters

References

Retrieved from "https://www.wikidoc.org/index.php?title=Acrodermatitis_chronica_atrophicans&oldid=1728552"